Lanean...

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

HDAC inhibitors (HDACI) are now emerging as one of the most promising new classes of drugs for the treatment of select forms of non-Hodgkin’s lymphoma (NHL). They are particularly active in T-cell lymphomas, possibly hodgkin’s lymphoma and indolent B cell lymphomas. Presently, two of these agents, v...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Zain, Jasmine, O’Connor, Owen A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2010
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3003796/
https://ncbi.nlm.nih.gov/pubmed/21132350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-010-9591-3
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!